[The expression of bcl-2, P53 and c-erbB-2 onco-proteins in breast cancer and their clinicopathological significance].
Lei Gao, Haiyan Ding, Yujiao Deng
Abstract
Lei Gao, Haiyan Ding, Yujiao Deng
Abstract
In order to study the interrelation between bcl-2, P53 and c-erbB-2 protein, their expression in 145 breast carcinomas were observed by immunohistochemical LSAB method. 19 cases were negative, 12 were positive for the three oncoproteins. 19 cases were positive for c-erbB-2 only. 20 positive for P53 only and 20 positive for bcl-2 only. 26 cases were positive for both P53 and c-erbB-2, 17 for both c-erbB-2 and bcl-2, 12 for both P53 and bcl-2. Strong inverse correlation was found between the expression of P53 and bcl-2 (P < 0.001). The P53 expression or the expression of both P53 and c-erbB-2 correlated with low histological grade, while the bcl-2 expression correlated with high histological grade (P < 0.05). The necrosis in tumors with only bcl-2 expression was less than those with c-erbB-2 or both c-erbB-2 and P53 expression (P < 0.02). Mitosis count was lower in tumors with only bcl-2 expression than those with expression of both c-erbB-2 and P53 (P < 0.05). The expression of c-erbB-2 and P53 proteins are associated with poor prognosis (P < 0.02, P < 0.05) but not affected by bcl-2. The results suggest that bcl-2, P53 and c-erbB-2 are involved in tumorigenesis and development of breast carcinoma with different biological effects.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In order to study the interrelation between bcl-2, P53 and c-erbB-2 protein, their expression in 145 breast carcinomas were observed by immunohistochemical LSAB method. 19 cases were negative, 12 were positive for the three oncoproteins. 19 cases were positive for c-erbB-2 only. 20 positive for P53 only and 20 positive for bcl-2 only. 26 cases were positive for both P53 and c-erbB-2, 17 for both c-erbB-2 and bcl-2, 12 for both P53 and bcl-2. Strong inverse correlation was found between the expression of P53 and bcl-2 (P < 0.001). The P53 expression or the expression of both P53 and c-erbB-2 correlated with low histological grade, while the bcl-2 expression correlated with high histological grade (P < 0.05). The necrosis in tumors with only bcl-2 expression was less than those with c-erbB-2 or both c-erbB-2 and P53 expression (P < 0.02). Mitosis count was lower in tumors with only bcl-2 expression than those with expression of both c-erbB-2 and P53 (P < 0.05). The expression of c-erbB-2 and P53 proteins are associated with poor prognosis (P < 0.02, P < 0.05) but not affected by bcl-2. The results suggest that bcl-2, P53 and c-erbB-2 are involved in tumorigenesis and development of breast carcinoma with different biological effects.
Key concepts: Immunohistochemistry, Carcinogenesis, Cancer research, P53 protein, Breast carcinoma, Breast cancer, P53 expression, ErbB